The paradigm of treating uterine conditions is shifting once again. We are moving away from the binary choice between surgery and medication, and toward a transition from “eradication therapy” to “suppressive therapy.” At the heart of this shift lies the oral hormonal inhibitor, Relugolix.
According to clinical studies published in 2025, patients treated with Relugolix demonstrated a significant reduction in menstrual volume, with some even reaching a state of amenorrhea. Uterine volume was also reported to decrease by an average of approximately 22%. Compared to traditional treatments, it offers reduced recovery burdens and superior patient accessibility, as it is an oral medication rather than an injectable.
The core of this drug lies in its mechanism. Relugolix acts as a GnRH antagonist, directly suppressing the pituitary gland to instantaneously block the secretion of female hormones. Unlike conventional GnRH agonists, it bypasses the initial “flare-up” of hormones, preventing the temporary exacerbation of symptoms and allowing for a more gradual recovery after treatment cessation. In terms of side-effect management, it is widely considered a clear advancement.
However, the clinical assessment is not so simple.
Relugolix does not eliminate lesions. Rather than removing uterine fibroids or adenomyosis tissue, it “suppresses” symptoms by altering the hormonal environment. Given that the condition is highly likely to revert to its original state once treatment is discontinued, it is difficult to classify this as a “curative” therapy.
In the context of fertility treatment, the utility of this medication is even more constrained. Hormonal suppression is synonymous with ovulation suppression. Throughout the treatment period, attempting pregnancy is effectively impossible. While it may stabilize the uterine environment, it inherently halts reproductive function.
In clinical practice, Relugolix is viewed less as a “cure” and more as a “time-management tool.” It is highly effective for pre-surgical symptom control, short-term management for patients nearing menopause, or as a strategic bridge to space out necessary interventions. However, for patients whose ultimate goal is pregnancy, a highly cautious approach is mandatory.
Technology is undeniably evolving, but the direction remains a subject of intense debate.
Is “reducing symptoms” equivalent to “curing the disease,” or is changing the fundamental course of the disease the true measure of success? Relugolix stands precisely on that boundary.
Disclaimer: This content is provided for informational purposes, based on reporting on infertility and various public data. Medical judgments and treatment decisions must always be made in consultation with professional medical personnel. Image: AI-generated (ChatGPT, OpenAI) / Visual reference for illustrative purposes only.